Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study

Matthew H Taylor
Courtney B Betts
Lauren Maloney
Eric Nadler
Alain Algazi

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Figure S2. Patient Disposition.

Enrolled
N=78

Randomized to pembrolizumab monotherapy
n=39

Received ≥1 dose of pembrolizumab monotherapy
n=39

Received pembrolizumab monotherapy throughout time on study
n=25

Discontinued study (n=25)
Death (n=16)
Study terminated by sponsor (n=7)
Withdrawal by patient (n=2)

Discontinued study (n=14)

Crossed over to pembrolizumab + acalabrutinib treatment
n=14

Received pembrolizumab + acalabrutinib throughout time on study
n=37

Discontinued study (n=37)
Death (n=23)
Study terminated by sponsor (n=7)
Other (n=6)
Withdrawal by patient (n=3)

Did not receive treatment (n=2)
Died before treatment (n=1)
Discontinued prior to treatment (n=1)